Copyright
©The Author(s) 2024.
World J Hepatol. Jul 27, 2024; 16(7): 1009-1017
Published online Jul 27, 2024. doi: 10.4254/wjh.v16.i7.1009
Published online Jul 27, 2024. doi: 10.4254/wjh.v16.i7.1009
Table 1 Baseline characteristics in 53 study subjects
| Characteristics | n (%) or range |
| Mean age (years) | 55 (28-80) |
| Age > 50 year-old | 35 (66) |
| Male:Female | 24:29 (45.3:54.7) |
| Ethnicity | |
| Asian | 51 (96.2) |
| Hispanic | 1 (1.9) |
| Other | 1 (1.9) |
| BMI ≥ 25 kg/m2 | 17 (32.1) |
| Clinical cirrhosis | 8 (15.1) |
| Spleen size > 12 cm | 4 (7.7) |
| HBV genotype | |
| A | 2/24 (8.3) |
| B | 15/24 (62.5) |
| C | 6/24 (25) |
| D | 1/24 (4.2) |
| HBeAg + | |
| Yes No | 15 (28.3) 38 (71.7) |
| Mean ALT (U/L) | 24.8 (7-108) |
| Mean AST (U/L) | 25.7 (15-89) |
| Mean creatinine (mg/dL) | 0.86 (0.5–1.7) |
| Mean APRI score | 0.37 (0.13-0.92) |
| Mean FIB-4 score | 1.66 (0.49-5.33) |
| Mean SWE score (kPa) | 7.05 (4-20.9) |
| Platelets ≤ 120 × 109/L | 6 (11.3) |
- Citation: Huynh T, Bui DM, Zhou TX, Hu KQ. Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years. World J Hepatol 2024; 16(7): 1009-1017
- URL: https://www.wjgnet.com/1948-5182/full/v16/i7/1009.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i7.1009